Expression of TCF3 in Burkitt's Lymphoma and Its Proliferative Effect and Prognostic Significance.
10.19746/j.cnki.issn.1009-2137.2022.05.020
- Author:
Li-Hua DONG
1
;
Jing-Jing HUANG
1
;
Jing LIU
1
;
Xue GAO
1
;
Jian-Wei DU
1
;
Yu-Fu LI
2
Author Information
1. Department of Hematology, Henan Institute of Hematology, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou 450008, Henan Province, China.
2. Department of Hematology, Henan Institute of Hematology, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou 450008, Henan Province, China .E-mail: zlyyliyufu0368@zzu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Burkitt's lymphoma;
TCF3;
cell proliferation;
prognosis
- MeSH:
Apoptosis;
Basic Helix-Loop-Helix Transcription Factors/therapeutic use*;
Burkitt Lymphoma/genetics*;
Humans;
Prognosis;
RNA, Small Interfering/therapeutic use*;
Sincalide/therapeutic use*
- From:
Journal of Experimental Hematology
2022;30(5):1435-1439
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the mutation and expression of TCF3 gene in Burkitt's lymphoma (BL), and explore its effect on the proliferation of BL cells and clinical efficacy and prognosis.
METHODS:The mutation and expression of TCF3 in tumor tissues from BL patients were observed by the second-generation sequencing and real-time quantitative PCR. The proliferation and apoptosis of lymphoma cells after TCF3 knocked down were observed by siRNA interference technique and CCK-8 method. Survival analysis was used to observe the relationship between TCF3 mutation and the treatment efficacy and prognosis of BL patients.
RESULTS:There were high frequency mutation rate (mutation rate was 23.7%) and high expression of TCF3 in BL patients. After TCF3 knocked down, cell proliferation was inhibited and apoptosis was promoted. In TCF3-siRNA group and control group, the cell proliferation rate at 48 h was (50.2±5.9)% and (96.6±11.4)%, and apoptosis rate was 30.1% and 1.5%, respectively, which showed significantly different between the two groups (P<0.001, P=0.005). The complete remission rate of patients with TCF3 mutation was low. The complete remission rate of mutant group and wild-type group was 44.4% and 82.8%, respectively (P=0.023). The 2-year progression-free survival rate and overall survival rate of the patients with TCF3 mutation was 55.6% and 61.0%, respectively, which was lower than 83.2% and 85.2% of the patients without mutation, but the differences were not statistically significant.
CONCLUSION:There are mutation and abnormal expression of TCF3 in patients with BL. Patients with TCF3 mutations have low remission rate and poor prognosis.
